-
-
Safety,Quality,Efficacy -
Safety,Quality,Efficacy -
Safety,Quality,Efficacy
Provide users with high-quality blood products
-
2024/06/25Shanghai RAAS was awarded the 15th China Listed Company Investor Relations Tianma Award.View Details
-
-462.jpg)
2024/05/29Shanghai RAAS was ranked fifth in the 2024 "SFEO Shanghai Productive Service Industry Brand Value List"View Details
-
-
2024/03/20Shanghai RAAS and Boehringer-Ingelheim Reached a Major Cooperation to Jointly Develop Innovative Drugs for Hemophilia
-
2023/12/18Some products of Shanghai RAAS cancel the limited payment scope of medical insurance
-
2023/03/01Shanghai RAAS was re-awarded the title of "Leading Enterprise of Oriental Beauty Valley".
-
About RAAS
Being vital for life saving, blood products are important national strategic reserve materials. Founded in 1988 and situated at No. 2009 Wangyuan Road, Fengxian District, Shanghai with a registered capital of RMB 6,740,787,907.00, Shanghai RAAS was listed on the Shenzhen Stock Exchange in June 2008 as a leading domestic blood products company that integrates source plasma collection, blood products research and development, production and sales.
-
36 years Extensive industry experience
-
5 units Production Bases
-
44 centers Plasma Donation Center
+0.20 (+3.13%)
RAAS Plasma Donation Center
As of Dec 2023, Shanghai RAAS and its subsidiaries had 44 plasma donation centers (including newly approved ) in China including those under construction, of which 18 are Shanghai RAAS , 19 are Tonrol Biopharmaceutical, 2 are Zhengzhou RAAS,3 are Zhejiang Haikang Biopharmaceutical and 2 are GuangXi RAAS, covering 11 provinces (autonomous regions) in Guangxi, Hunan, Hainan, Shaanxi, Anhui, Guangdong, Inner Mongolia, Zhejiang, Hubei, Jiangxi and Shandong.
-
18 centers Shanghai RAAS (including one subcenter)
-
19 centers Tonrol Biopharmaceutical
-
2 centers Zhengzhou RAAS
-
3 centers Zhejiang Haikang Biopharmaceutical
-
2 centers GuangXi RAAS
